The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy

BMC Ophthalmology

Debate

Maxwell P Treacy¹  Tara P Hurst² 

[1] Royal Victoria Eye and Ear Hospital, Adelaide Road, Dublin 2, Dublin, Ireland;School of Science and Technology, Nottingham Trent University, NG11 8NS, Clifton Lane, Nottingham, United Kingdom;

关键词: Diabetes;    Diabetic retinopathy;    Intraocular;    Fenofibrate;    TZDs;    PPARs;   

DOI  :  10.1186/1471-2415-12-46

 received in 2012-05-25, accepted in 2012-08-29,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundSystemic therapeutics targeting the peroxisome proliferator-activated receptors have been found to be beneficial in the treatment of diabetic retinopathy. In this paper, we provide a rationale for the use of these therapeutics as intraocular agents. In addition, we introduce the peroxisome proliferator-activated receptors and describe their functions in response to the drugs.DiscussionBased on the evidence of large-scale clinical studies investigating the systemic administration of fenofibrate, this ligand for peroxisome proliferator-activated receptor-α is potentially a good candidate for intraocular delivery. Here, we describe the mechanisms by which it might be acting to improve diabetic retinopathy, its relative safety and we speculate on how it could be developed for intraocular delivery.SummaryIn this paper, we provide a rationale for the further investigation of peroxisome proliferator-activated receptor-α agonists as intraocular agents for the treatment of diabetic retinopathy.

【 授权许可】

CC BY   
© Treacy and Hurst; licensee BioMed Central Ltd. 2012